论文部分内容阅读
目的：观察肾复康Ⅱ号胶囊治疗脾肾气虚兼血瘀证慢性肾小球肾炎的临床疗效及安全性。方法将60例患者随机分为治疗组和对照组。对照组采用西医一般常规治疗；治疗组在对照组治疗的基础上加用肾复康Ⅱ号胶囊。两组治疗8周后，观察患者尿常规、尿蛋白定性、尿红细胞定性、24h尿蛋白定量、血肌酐、尿素氮结果，中医症状及临床总疗效。结果治疗组临床总有效率优于对照组（P＜0．05）；治疗组在降低患者尿蛋白定性、尿红细胞定性、24h尿蛋白定量方面优于对照组，但尚不能认为治疗组在改善尿素氮、血肌酐水平方面优于对照组；治疗组中医证候疗效优于对照组（P＜0．05）；治疗组在改善中医临床症状方面明显优于对照组；两组试验过程中均未出现明显不良反应。结论肾复康Ⅱ号胶囊治疗慢性肾小球肾炎能够缓解患者临床症状，减少蛋白尿、血尿，保护肾功能，用药安全，疗效确切，值得进一步实验研究及临床推广。“,”s:Objective To observe clinical efficacy and safety of ShenfukangⅡcapsule in treatment of chronic glomerulonephritis with spleenandkidneyqiandbloodstasistype.Method 60caseswererandomlydividedintotreatmentgroupandcontrolgroup.Thecontrol group was treated with conventional treatment;the treatment group was treated with ShenfukangⅡcapsule based on the control group.After 8 weeks treatment, the two groups in patients with urine routine, urine protein, urine red blood cells, 24h urine protein, serum creatinine and urea nitrogen symptoms and clinical effects were observed.Result The total effective rate of the treatment group was better than the con-trol group(P<0.05);the treatment group was superior to the control group in reducing urine protein, urine red blood cell and 24h urine pro-tein, but still can not be considered that the treatment group was better than the control group in the improvement of urea nitrogen and serum creatinine level;the total effective rate of TCM syndromes of the treatment group was better than the control group(P<0.05);the treatment group in improving clinical symptoms of TCM was superior to the control group; there was no obvious adverse reaction in the two groups. Conclusions ShenfukangⅡcapsule in treating chronic glomerulonephritis patients can relieve symptoms and reduce proteinuria, hematuria, and protect renal function, medication safety and efficacy,is worthy of further experimental research and clinical promotion.